Trial Profile

A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Farletuzumab ecteribulin (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Bristol-Myers Squibb

21 Nov 2024 Status changed from recruiting to active, no longer recruiting.
16 Aug 2023 Planned End Date changed from 11 Sep 2026 to 11 Oct 2026.
16 Aug 2023 Planned primary completion date changed from 28 Jun 2024 to 5 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com